AbbVie Inc. (FRA:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 346.62B |
| Revenue (ttm) | 50.83B |
| Net Income (ttm) | 2.00B |
| Shares Out | n/a |
| EPS (ttm) | 1.13 |
| PE Ratio | 173.20 |
| Forward PE | 16.71 |
| Dividend | 5.86 (2.97%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 16 |
| Average Volume | 76 |
| Open | 195.20 |
| Previous Close | 197.40 |
| Day's Range | 194.20 - 197.20 |
| 52-Week Range | 147.00 - 209.50 |
| Beta | n/a |
| RSI | 51.30 |
| Earnings Date | Jan 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Notable ETF Inflow Detected - XLV, JNJ, ABBV, MRK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
ABBV Quantitative Stock Analysis
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim v...
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of ...
2 Top Dividend Stocks to Buy Now and Hold For a Decade
Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues to grow its dividend through tough times.
AbbVie (ABBV) Faces New Generic Competition for Restasis
AbbVie (ABBV) Faces New Generic Competition for Restasis
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating
Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
The stocks listed below yield between 2.7% and 3.5%. They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 2.27% on an annualized basis producing an average annual return of 15.03%. Currently, AbbVie has a market capitalization of $...
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Treatment
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Treatment
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).
SKYRIZI (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
SKYRIZI (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s dis...
8 Dividend Stocks Every Investor Should Consider
Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
CollPlant's Strategic Focus with AbbVie (ABBV) Gains Spotlight
CollPlant's Strategic Focus with AbbVie (ABBV) Gains Spotlight
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster inno...
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
5 Dividend Stocks to Hold for the Next 10 Years
These dividend stocks represent the communications services, energy, financial services, healthcare, and real estate sectors. All of them have attractive dividend yields.
The Zacks Analyst Blog JPMorgan, Netflix, AbbVie and Ohio Valley Banc
JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.
Top Research Reports for JPMorgan Chase, Netflix & AbbVie
JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
Unpacking the Latest Options Trading Trends in AbbVie
Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE: ABBV) revealed 9 unusual trades. Delving into the details, we found 11% of traders w...
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 14.31%. Currently, AbbVie has a market capitalization of $4...
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and the...
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.